Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New Equine Virus test launched
NEV is often misdiagnosed or hidden by other diseases that cause similar symptoms.
Test to prevent misdiagnosis of often fatal disease

The first commercial diagnostic test for New Equine Virus (NEV) has been launched.

First discovered in 2013, NEV is often misdiagnosed or hidden by other diseases that cause similar symptoms, such as anaemia and neurological problems.

It is most often confused with the Swamp Fever virus (EIAV) and Equine Herpesvirus (EHV).

Now, thanks to research by equine biotech firm Equigerminal, vets, laboratories and horse owners will be able to identify this often fatal disease and administer the appropriate treatment.

The test requires a vet to take a blood sample from the horse and send it to the Equigerminal lab. The blood is then analysed and the results are returned to the owner or vet.

When the results are returned, the horse can be given treatment and the spread of the disease can be prevented. Currently, treatment is aimed towards improving the general wellbeing of the horse, monitoring its health and boosting the immune system.

NEV was discovered by Portuguese scientist and veterinary surgeon Isabel Fidalgo Carvalho while completing her PhD in Equine Sciences at the Universities of Oporto and Pittsburgh.

“During my time at University and at Equigerminal, I noticed unusual anaemia and severe neurological signs in horses, which in my PhD I wrongly hypothesized to be attributed to Swamp Fever,” she said. “I then realised, through the samples, that this virus was actually closer to equine HIV – New Equine Virus, or NEV”.

After her discovery, Carvalho launched Equigerminal with fellow scientist Alexandre Vieira Pires.

“We have spent the last five years developing a diagnostic test and a potential cure for NEV.” explains Pires.“We now need to raise awareness of the problem and help vets to diagnose this disease correctly.”

Become a member or log in to add this story to your CPD history

NOAH board elected

News Story 1
 NOAH has elected its board team, as part of its annual general meeting.

Ned Flaxman, general manager at Norbrook Laboratories Ltd, retains his position as chair, which he has held since June 2023.

Caitrina Oakes (Vetoquinol) remains past chair, and Matthew Frost (Elanco) remains treasurer.

Andrew Buglass (Eco Animal Health Ltd), Oya Canbas (Zoetis) and Charlotte Covell (Virbac) are newly elected vice-chairs. Meanwhile Roy Geary (Ceva) and John Toole (Beaphar) join the NOAH Board of Management.

Dawn Howard, NOAH chief executive, said: "I congratulate all the officers and board members who have been elected or re-elected today.

"I look forward to working together to ensure that NOAH continues to deliver at the highest standard for its members." 

Click here for more...
News Shorts
Series two of SCOPS podcast launched

The Sustainable Control of Parasites in Sheep (SCOPS) Group has launched the second series of its podcast.

The series will comprise four episodes, with topics including the sustainable use of parasite treatments, effective quarantining, administrating a mid/late season dose, and tackling resistance to multiple groups of anthelmintic.

Kevin Harrison, Gloucestershire sheep farmer and SCOPS chair, said: "The podcast is suitable for sheep farmers, vets and advisers, so please subscribe and spread the word if you enjoy the content.

"All episodes from series one are still available online, as well as the new episodes being added."

The podcast is available on the SCOPS website and other podcast platforms.